|
|
(62 intermediate revisions by 7 users not shown) |
Line 1: |
Line 1: |
| {{BNU-CHINA/partials/header}} | | {{BNU-CHINA/partials/header}} |
| {{BNU-CHINA/partials/nav | PROJECT=focus}} | | {{BNU-CHINA/partials/nav | PROJECT=focus}} |
| + | {{BNU-CHINA/article/theme | color=#003a6c}} |
| + | |
| <html> | | <html> |
| <div class="main-container"> | | <div class="main-container"> |
− | <div id="page-heading" class="container-fluid page-heading" style="background-image: url(https://static.igem.org/mediawiki/2016/f/f4/T--BNU-China--project.jpg);"> | + | <div class="container-fluid page-heading" style="background-image: url(https://static.igem.org/mediawiki/2016/f/f4/T--BNU-China--project.jpg);"> |
− | <h3> PROJECT </h3> | + | <h3> Background </h3> |
| </div> | | </div> |
− | <div style="background-image: url(https://static.igem.org/mediawiki/2016/e/e5/T--BNU-China--landingImage.jpg); background-size: 100%;">
| |
− | <div class="container page-story">
| |
| | | |
− | <article id="project" class="col-lg-10 col-lg-offset-1 col-md-12 col-md-offset-0 col-sm-offset-0 col-sm-12">
| + | <div class="page-story"> |
| + | |
| + | <article id="project" class="col-lg-10 col-lg-offset-1 col-md-12 col-md-offset-0 col-sm-offset-0 col-sm-12"> |
| <header class="page-header"> | | <header class="page-header"> |
− | <h1>Project</h1> | + | <h1>Background</h1> |
− | <small id="secondary-page-header">This is our Modeling Design</small>
| + | |
| </header> | | </header> |
| | | |
− | <h2>Background</h2> | + | <h2>Overview</h2> |
− | <p>Cancer is a large class of malignant diseases, 14 million new cases arising and causing over 8 million deaths per year. Which is the second most lethal disease in the world.<sub>[1]</sub></p> | + | <p>Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body, and it is the second most common cause of death worldwide, leading to 14 million new cases and over 8 million deaths per year<sup><a href="https://2016.igem.org/Team:BNU-China/Project#ref-1">[1]</a></sup>. Besides, The financial costs of treating cancer were estimated at 1.16 trillion US dollars per year as of 2010. It has become one of the great challenges human is facing nowadays.</p> |
− | <figure> | + | <figure class="text-center"> |
− | <img src="https://static.igem.org/mediawiki/2016/b/b2/T--BNU-China--cancer.jpg" style="width: 60%;"> | + | <img src="https://static.igem.org/mediawiki/2016/b/b2/T--BNU-China--cancer.jpg" width="65%"> |
| <figcaption> | | <figcaption> |
| Fig.1 Death from cancer per million persons in 2012 | | Fig.1 Death from cancer per million persons in 2012 |
| </figcaption> | | </figcaption> |
| </figure> | | </figure> |
− | <p>Anti-microtubule agents , one of the most efficient medicines to treat many cancers including breast cancer、ovarian cancer and so on , are plant-derived chemicals that block cell mitosis by interfering with microtubule function . Microtubule is an important cellular structure composed of two proteins; α-tubulin and β-tubulin. They are hollow rod shaped structures that are required for cell division, among other cellular functions. [2] Microtubules are dynamic structures, which means that they are permanently in a state of assembly and disassembly. And the anti-microtubule agents can inhibit the dynamic balance of microtubule, leading to the termination of cell mitosis and inducing the apoptosis of tumor cells.</p> | + | <p>In order to conquer this serious problem, many medical scientists are devoted to exploit medicines that can target cancer cells. In 1962, paclitaxel was discovered in the bark of the Pacific yew, <i>Taxus brevifolia</i>, giving the name “paclitaxel”. Shortly after its discovery, taxanes have demonstrated a unique ability to palliate the symptoms of many types of advanced cancers, including carcinoma of the ovary, lung, head, neck, bladder, and esophagus. Good efficacy and little side effect quickly made the taxane class a most common addition to the chemotherapy against cancer in the past several decades.</p> |
− | <p>Anti-microtubule agents can be divided into two types : one inhibit assembly , such as vinca alkaloids、colchicine、podophyllotoxin and so on . The other inhibit disassembly , including taxanes、epothilones etc. Taxanes is the most famous among them.</p>
| + | |
− | <p>Paclitaxel was discovered in 1962, isolated from the bark of the Pacific yew, Taxus brevifolia, thus its name “paclitaxel”. After only a brief period, the taxanes have demonstrated a unique ability to palliate the symptoms of many types of advanced cancers, including carcinoma of the ovary, lung, head and neck, bladder, and esophagus. Due to its good efficacy and slight side effect, the taxane class of anti-microtubule anticancer agents is perhaps the most important addition to the chemotherapeutic armamentarium against cancer over the past several decades.</p>
| + | <figure class="text-center"> |
− | <figure> | + | <img src="https://static.igem.org/mediawiki/2016/7/70/T--BNU-China--taxol2.jpg" width="65%" > |
− | <img src="https://static.igem.org/mediawiki/2016/7/70/T--BNU-China--taxol2.jpg"> | + | |
| <figcaption> | | <figcaption> |
− | Fig.2 Ball-and-stick model of the Taxol | + | Fig.2 Ball-and-stick model of the taxol |
| </figcaption> | | </figcaption> |
| </figure> | | </figure> |
− | <p>Paclitaxel and other anti-microtubule medicines make a great success, which inspires many factories to extract these compounds, leading more and more famers to cultivate plants containing these compounds widely. Moreover, there are more and more scientists devote to study them. However, under this circumstance, many problems have alsobeen caused.</p> | + | <p>The great commercial success of Paclitaxel and other anti-microtubule medicines has inspired pharmaceutical companies to extract and test similar compounds, farmers to grow related plants. So an effective method is being needed urgently to discover many other similar compounds. Moreover, testing the concentration of paclitaxel from fermentation broths or plants are in high demand.</p> |
− | <p>As to our project this year, we modified the homo sapiens tubulin alpha 1a , connected it with luciferase report gene’s N terminal or C terminal , and we put the modified α-tubulin and β-tubulin into E-coli to reduce them . Then we will get a kit containing the tubulins and buffer which has the appropriate condition verified by experiments. We call the kit “taxolight”, and it can do these things:</p> | + | <p>How to test the taxol and screening other compounds?<br />We determine to use microtubule for assisting.</p> |
− | <h4>1. drug screen</h4> | + | <p>As we all know, the mechanism of taxol is to kill cancer cells by obstructing the function of microtubule and consequently blocking cell division. Microtubules are a kind of important cellular structure composed of two monomers: α-tubulin and β-tubulin. These hollow rod shaped proteins are required for many cellular activities including cell division and transportation.<sup><a href="https://2016.igem.org/Team:BNU-China/Project#ref-2">[2]</a></sup> A dynamic equivalence are found in microtubules, meaning that protein monomers are assembling and disassembling at every moment. The anti-microtubule agents can destroy the dynamic balance in microtubules, hence terminating cell mitosis and inducing the tumor cell apoptosis.</p> |
− | <p>Anti-cancer agents especially paclitaxel have showed their magnificent power in clinical application, but also are a little unsatisfactory. We still need to look for new drugs that more effective.</p> | + | <p>There are two types of anti-microtubule agents. One type inhibits assembly, such as vinca alkaloids, colchicine, podophyllotoxin and etc. The other type interferes disassembly, like taxanes and epothilones.</p> |
− | <p>The existing method to screen anti-microtubule agents needs purifying tubulins of mammalian brains. It relies on the features of tubulins that the solution turbid will increase when then polymerize in vitro under 37℃ centigrade. So using this method, we can get a polymerization curve shaped sigmoid formed by the liquid OD value to the soaking time, correspondingly, we can also get a de-polymerization curve when putting the tubulins into ice. When adding different anti-microtubule agents, polymerization of "S" type curve or pour de-polymerization of "S" type curve has different effects, and we can determine the role of the drug according to the change of curve.</p> | + | <p>As for the discovery of anti-cancer compounds, we narrow down our sight to the anti-microtubule agents which are of great significance in cancer treatments.</p> |
− | <p>Our project provides a new idea on the drug screen of anti-microtubule agents: using our kit, add the two kinds of quantitative modified α-tubulins withβ-tubulins and buffer, and put the quantitative sample, and then measure its fluorescence intensity. Paclitaxel can be set as a standard, and we can compare the new medicine with paclitaxel by comparing the fluorescence intensity. In this way, the primary invitro screening of compounds that can influence microtubules can be carried out using our kit, to further research and development of new anti-microtubule agents.</p> | + | <p>As for our project this year, we modified the homo sapiens α-tubulin, ligated it with N/C terminal of the luciferase report gene fragments. Based on the principles of synthetic biology, we aimed to express the fusion proteins with α-tubulin and signaling residues. Then we made a kit containing the fusion α-tubulins and non-fusion β-tubulins with buffer which has an appropriate condition verified by experiments. We call the kit “taxolight”, and through which we can achieve these things below:</p> |
− | </article>
| + | <h3>Screening with high feasibility</h3> |
− | </div>
| + | <p>Anti-cancer agents especially paclitaxel have showed their powerful ability in clinical application. However, we still need to look for new drugs that are more effective.</p> |
| + | <p>The existing screening method of anti-microtubule agents needs to purify tubulins coming from mammalian brains. It heavily relies on the turbidity of tubulin solutions when they aggregate or disaggregate under certain temperatures <i>in vitro</i>. Once using this method, we can get a “S”-type standard aggregation curve based on the liquid OD value and the incubation time. Similarly, we can also get a standard disaggregation curve. When added different anti-microtubule agents, the aggregation/disaggregation curve will change correspondingly. Thus we can determine the role of the drug according to the change of curve.</p> |
| + | <p>The defects of this method are shown below:</p> |
| + | <ol> |
| + | <li>The operation of extracting and purifying tubulin from animal brain is very complicated, and the experiment must be done within an hour after killing the animal. At the same time, the price of reagents in this experiment is expensive. The experiment period is long which takes no less than 3 days.</li> |
| + | <li>The wave length of measuring OD is 350nm, which is between ultraviolet light and visible light and always leads to a huge deviation. Also, the requirement of the testing instruments is high, quartz containers are needed as well, which cost a lot.</li> |
| + | </ol> |
| + | <p>Our project avoids these drawbacks, and provides a new insight for the anti-microtubule drug screening. What we need is just a fluorescence microscope by using our kit.</p> |
| + | <p>Take paclitaxel as a control, we could test the fluorescence intensity of new medicine compared with paclitaxel's. In this way, further research and development of new anti-microtubule agents can be carried out easily than before.</p> |
| + | |
| + | <h3>Detection in high sensitivity</h3> |
| + | <p>HPLC/RP-HPLC is one of the most common method to detect paclitaxel now. It relies on pumps to pass the sample through a column filled with solid adsorbent materials. Each component in the sample interacts differently with the adsorbent material, causing different flow rates and leading to the separation of the components as they flow out of the column.</p> |
| + | <figure class="text-center"> |
| + | <img src="https://static.igem.org/mediawiki/2016/c/c1/T--BNU-China--HPLC.jpg" width="65%"> |
| + | <figcaption> |
| + | Fig.3 The process of HPLC |
| + | </figcaption> |
| + | </figure> |
| + | <p>This is a time-consuming process which is very unfavorable to the studies in laboratory. For example, in a laboratory which producing paclitaxel from fungus, detecting the concentration of the product may delay experiment process if there were no paclitaxel at all. So we need to develop an effective method to rapidly detect whether taxanes exist or not before measuring concentration. Our kit can reach the goal in order to accelerate research progresses.</p> |
| + | <h3>Concentration detection</h3> |
| + | <p>Apart from our former achievements, optimization is also needed. An intensity-concentration database of certain medicines (e.g. paclitaxel) is being planned, then we can use our “taxolight” to determine the concentration of this certain medicine conveniently.</p> |
| + | <p>There is a limited issue that the sample solution must be ensured not containing other anti-microtubule agents. Nevertheless, it is still useful. For example, farmers who plant taxus can apply our kit to detect the concentration of taxanes in there plants. Moreover, factory can use our kit to test the concentration of taxol in their fermentation broth. In conclusion, our product can be popularized in many agent-specific tests.</p> |
| + | |
| + | |
| + | <div class="reference"> |
| + | <ol> |
| + | <li id="ref-1">World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 1.1. d5ISBN 9283204298.</li> |
| + | |
| + | <li id="ref-2">Rowinsky EK, Donehower RC (Oct 1991). "The clinical pharmacology and use of anti-microtubule agents in cancer chemotherapeutics". Pharmacology.& Therapeutics. 52 (1): 35–84. doi:10.1016/0163-7258(91)90086-2. PMID 1687171.</li> |
| + | </ol> |
| + | </div> |
| + | |
| + | </article> |
| + | |
| + | </div> |
| | | |
| + | <div id="footer"> |
| + | <div id="footer-div"> |
| + | <ul id="footer-ul"> |
| + | <li><a href="https://2016.igem.org/Team:BNU-China">Home</a></li> |
| + | <li><a href="https://2016.igem.org/Team:BNU-China/Project">Project</a></li> |
| + | <li><a href="https://2016.igem.org/Team:BNU-China/Model">Model</a></li> |
| + | <li><a href="https://2016.igem.org/Team:BNU-China/Achievements">Achievements</a></li> |
| + | <li><a href="https://2016.igem.org/Team:BNU-China/Integrated_Practices">Practices</a></li> |
| + | <li><a href="https://2016.igem.org/Team:BNU-China/Safety">Safety</a></li> |
| + | <li><a href="https://2016.igem.org/Team:BNU-China/Team">Team</a></li> |
| + | </ul> |
| + | <span>© 2016 BNU</span> |
| </div> | | </div> |
| </div> | | </div> |
| | | |
| </html> | | </html> |